Next Article in Journal
Cannabinoids and Dementia: A Review of Clinical and Preclinical Data
Next Article in Special Issue
Clinical Toxicities of Histone Deacetylase Inhibitors
Previous Article in Journal
The Role of Cannabinoid Receptors in the Descending Modulation of Pain
Previous Article in Special Issue
Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies
Pharmaceuticals 2010, 3(8), 2674-2688; doi:10.3390/ph3082674

Overview of Histone Deacetylase Inhibitors in Haematological Malignancies

1,* , 1,3, 2, 2 and 2,3
1 Cancer Immunology Research, Peter MacCallum Cancer Centre, Melbourne, Australia 2 Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Australia 3 University of Melbourne, Parkville, Melbourne, Australia
* Author to whom correspondence should be addressed.
Received: 23 July 2010 / Revised: 12 August 2010 / Accepted: 13 August 2010 / Published: 17 August 2010
(This article belongs to the Special Issue HDAC Inhibitors)
View Full-Text   |   Download PDF [163 KB, uploaded 17 August 2010]


Histone deacetylase inhibitors (HDACi) can induce hyperacetylation of both histone and non-histone target resulting in epigenetic reprogramming and altered activity, stability and localisation of non-histone proteins to ultimately mediate diverse biological effects on cancer cells and their microenvironment. Clinical trials have demonstrated single agent HDACi to have activity in hematological malignancies, in particular T-cell lymphoma and Hodgkin lymphoma. Combination strategies with standard therapies based on pre-clinical data are being employed with significant success due to their excellent side effect profile. Correlative studies will provide valuable information on the sub-groups of patients more likely to respond or be resistant to HDACi therapy, while long-term monitoring for toxicities is also needed.
Keywords: Histone deacetylase inhibitors; Clinical studies; Haematology Histone deacetylase inhibitors; Clinical studies; Haematology
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
MDPI and ACS Style

Bishton, M.J.; Johnstone, R.W.; Dickinson, M.; Harrison, S.; Prince, H.M. Overview of Histone Deacetylase Inhibitors in Haematological Malignancies. Pharmaceuticals 2010, 3, 2674-2688.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert